Streetbeat News

Earnings

SBUX

Howard Schultz, former CEO of Starbucks, opposes a potential settlement between Starbucks and activist investor Elliott Investment Management. Schultz, who remains a significant shareholder, has publicly criticized the company's leadership and performance. Starbucks has faced a 20% decline in share price since the start of 2024 and has cut its financial guidance twice this year. The company is set to announce its fiscal third-quarter results soon.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:39 pm

OPTT

PGNT

Paragon Technologies, a major shareholder of Ocean Power Technologies (OPTT), advises shareholders to vote against OPTT's proposal to increase authorized shares by 100 million. OPTT's fiscal 2024 results show a loss of $27.4 million, up from $26.3 million in fiscal 2023.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:34 pm

TBNK

Territorial Bancorp (NASDAQ:TBNK) reported a Q2 EPS of $(0.09), missing the $(0.03) estimate by 200%. Sales were $8.90M, missing the $9.03M estimate by 1.46%. This represents a significant decline from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:33 pm

HFBL

Home Federal Bancorp (NASDAQ:HFBL) reported a significant decrease in quarterly earnings, with Q4 EPS dropping to $0.21 from $0.40 year-over-year, marking a 47.5% decline.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:32 pm

AFBI

Affinity Bancshares (NASDAQ:AFBI) reported a Q2 EPS of $0.16, down 33.33% from $0.24 YoY.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:31 pm

NPK

National Presto Industries (NYSE:NPK) reported a 10.39% increase in Q2 EPS to $0.85 and a 7.80% increase in sales to $85.10 million compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:29 pm

CGTX

Cognition Therapeutics, Inc. (NASDAQ:CGTX) will host an investor webcast on July 29, 2024, to discuss results from the Phase 2 SHINE study of CT1812 in mild-to-moderate Alzheimer's disease. The webcast will cover clinical efficacy, safety, and biomarker findings. Results will also be presented at the Alzheimer's Association's International Conference.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:13 pm

DAVE

Over the past three months, 10 analysts have evaluated Dave (NASDAQ:DAVE), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $62.2, with a high of $75.00 and a low of $45.00. Dave has shown strong financial performance with significant revenue growth, high net margin, ROE, and ROA, and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 8:02 pm

ALHC

Analysts have provided mixed ratings for Alignment Healthcare (NASDAQ:ALHC) in the latest quarter, with a notable increase in the average 12-month price target to $9.25. The company's financial performance shows strong revenue growth but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 8:01 pm

VKTX

Viking Therapeutics (NASDAQ:VKTX) has seen significant bullish options activity, with 46% of trades being bullish and 30% bearish. The stock price is currently up 2.5% at $66.3, with analysts setting an average target price of $104.33. Notable options trades include calls with strike prices ranging from $40 to $100.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 8:01 pm